FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126191769> ?p ?o ?g. }

• W3126191769 abstract "The effect of various reduced doses of verteporfin photodynamic therapy (PDT) on choroidal blood flow in chronic central serous chorioretinopathy (CSC) remains unclear. Therefore, this study aimed to evaluate choroidal blood flow after half-dose PDT (1/2PDT) and one-third dose PDT (1/3PDT) with verteporfin for chronic CSC using laser speckle flowgraphy and spectral-domain optical coherence tomography.Twenty-seven eyes of 27 patients with serous retinal detachment (SRD) caused by chronic CSC for more than 6 months were included in this study. Patients were divided into the 1/2PDT (n = 12; January 2018 to July 2019) and 1/3PDT (n = 15; August 2016 to December 2017) groups based on the treatment period. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), and mean blur rate in the macular area (m-MBR) and optic nerve head (ONH-MBR) were obtained using laser speckle flowgraphy and evaluated at baseline (pre-treatment), and 2 weeks, 1 month, 3 months, and 6 months after treatment.We found that SRD disappeared after 1 month in 92 and 93% of patients' eyes in the 1/2PDT and 1/3PDT groups, respectively. Recurrence of SRD was observed in one eye at the 6-month follow-up after 1/2PDT and two eyes at the 3-month follow-up after 1/3PDT. No significant improvement was observed in baseline BCVA in the 1/3PDT and 1/2PDT groups. The average m-MBR against baseline significantly decreased at 2 weeks and 1, 3, and 6 months in the 1/2PDT group. The average m-MBR against baseline decreased significantly only at the 2 weeks follow-up in the 1/3PDT group. The average rate of change in the CCT against baseline decreased significantly throughout for up to 6 months in the 1/2PDT group and for up to 3 months in the 1/3PDT group. No significant fluctuation was observed in the ONH-MBR.Here, PDT significantly affected choroidal blood flow depending on the verteporfin dose in chronic CSC.This trial was retrospectively registered ( UMIN000026850 ; Approval date 03/04/2017)." @default.
• W3126191769 created "2021-02-15" @default.
• W3126191769 creator A5026898267 @default.
• W3126191769 creator A5034787394 @default.
• W3126191769 creator A5038408725 @default.
• W3126191769 creator A5045172459 @default.
• W3126191769 creator A5068662674 @default.
• W3126191769 creator A5091304951 @default.
• W3126191769 date "2021-05-31" @default.
• W3126191769 modified "2023-10-14" @default.
• W3126191769 title "Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy" @default.
• W3126191769 cites W1922969769 @default.
• W3126191769 cites W1976633908 @default.
• W3126191769 cites W1977261713 @default.
• W3126191769 cites W1978681826 @default.
• W3126191769 cites W1986679001 @default.
• W3126191769 cites W1988435423 @default.
• W3126191769 cites W1988957744 @default.
• W3126191769 cites W1999439444 @default.
• W3126191769 cites W2001625184 @default.
• W3126191769 cites W2006093387 @default.
• W3126191769 cites W2015193321 @default.
• W3126191769 cites W2016202757 @default.
• W3126191769 cites W2047374797 @default.
• W3126191769 cites W2057417542 @default.
• W3126191769 cites W2064327993 @default.
• W3126191769 cites W2068279199 @default.
• W3126191769 cites W2075218366 @default.
• W3126191769 cites W2136042539 @default.
• W3126191769 cites W2293337776 @default.
• W3126191769 cites W2320616723 @default.
• W3126191769 cites W2329158489 @default.
• W3126191769 cites W2338016719 @default.
• W3126191769 cites W2346496046 @default.
• W3126191769 cites W2400450999 @default.
• W3126191769 cites W2432677447 @default.
• W3126191769 cites W2471233652 @default.
• W3126191769 cites W2519818721 @default.
• W3126191769 cites W2558092520 @default.
• W3126191769 cites W2563389038 @default.
• W3126191769 cites W2782004117 @default.
• W3126191769 cites W2803624845 @default.
• W3126191769 cites W2907155320 @default.
• W3126191769 cites W2909814657 @default.
• W3126191769 cites W2911693030 @default.
• W3126191769 cites W2958114009 @default.
• W3126191769 cites W2966012275 @default.
• W3126191769 cites W3021895581 @default.
• W3126191769 doi "https://doi.org/10.1186/s12886-021-01980-w" @default.
• W3126191769 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8165776" @default.
• W3126191769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34053440" @default.
• W3126191769 hasPublicationYear "2021" @default.
• W3126191769 type Work @default.
• W3126191769 sameAs 3126191769 @default.
• W3126191769 citedByCount "5" @default.
• W3126191769 countsByYear W31261917692022 @default.
• W3126191769 countsByYear W31261917692023 @default.
• W3126191769 crossrefType "journal-article" @default.
• W3126191769 hasAuthorship W3126191769A5026898267 @default.
• W3126191769 hasAuthorship W3126191769A5034787394 @default.
• W3126191769 hasAuthorship W3126191769A5038408725 @default.
• W3126191769 hasAuthorship W3126191769A5045172459 @default.
• W3126191769 hasAuthorship W3126191769A5068662674 @default.
• W3126191769 hasAuthorship W3126191769A5091304951 @default.
• W3126191769 hasBestOaLocation W31261917691 @default.
• W3126191769 hasConcept C118487528 @default.
• W3126191769 hasConcept C120665830 @default.
• W3126191769 hasConcept C121332964 @default.
• W3126191769 hasConcept C126322002 @default.
• W3126191769 hasConcept C150173356 @default.
• W3126191769 hasConcept C158846371 @default.
• W3126191769 hasConcept C178790620 @default.
• W3126191769 hasConcept C185592680 @default.
• W3126191769 hasConcept C2776694393 @default.
• W3126191769 hasConcept C2777093970 @default.
• W3126191769 hasConcept C2778257484 @default.
• W3126191769 hasConcept C2780827179 @default.
• W3126191769 hasConcept C2781148688 @default.
• W3126191769 hasConcept C2781323092 @default.
• W3126191769 hasConcept C2781359195 @default.
• W3126191769 hasConcept C71924100 @default.
• W3126191769 hasConceptScore W3126191769C118487528 @default.
• W3126191769 hasConceptScore W3126191769C120665830 @default.
• W3126191769 hasConceptScore W3126191769C121332964 @default.
• W3126191769 hasConceptScore W3126191769C126322002 @default.
• W3126191769 hasConceptScore W3126191769C150173356 @default.
• W3126191769 hasConceptScore W3126191769C158846371 @default.
• W3126191769 hasConceptScore W3126191769C178790620 @default.
• W3126191769 hasConceptScore W3126191769C185592680 @default.
• W3126191769 hasConceptScore W3126191769C2776694393 @default.
• W3126191769 hasConceptScore W3126191769C2777093970 @default.
• W3126191769 hasConceptScore W3126191769C2778257484 @default.
• W3126191769 hasConceptScore W3126191769C2780827179 @default.
• W3126191769 hasConceptScore W3126191769C2781148688 @default.
• W3126191769 hasConceptScore W3126191769C2781323092 @default.
• W3126191769 hasConceptScore W3126191769C2781359195 @default.
• W3126191769 hasConceptScore W3126191769C71924100 @default.
• W3126191769 hasIssue "1" @default.
• W3126191769 hasLocation W31261917691 @default.
• W3126191769 hasLocation W31261917692 @default.

• next